Marshall Wace, LLP Eliem Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 229,889 shares of ELYM stock, worth $944,843. This represents 0.0% of its overall portfolio holdings.
Number of Shares
229,889
Previous 36,738
525.75%
Holding current value
$944,843
Previous $150,000
529.33%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ELYM
# of Institutions
67Shares Held
44.3MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.32MShares$5.41 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.3MShares$5.34 Million0.62% of portfolio
-
Kynam Capital Management, LP Princeton, NJ1.03MShares$4.23 Million0.36% of portfolio
-
Tang Capital Management LLC San Diego, CA1MShares$4.11 Million0.19% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...